Inga Saknite1,2, James R Patrinely1,3, Zijun Zhao1,3, Heidi Chen4, Alicia Beeghly-Fadiel5, Tae Kon Kim6,7, Madan Jagasia7,8, Michael Byrne6,7, Eric R Tkaczyk1,3,7,9. 1. Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia, Riga, Latvia. 3. Dermatology Service and Research Service, Tennessee Valley Healthcare System, US Department of Veterans Affairs, Nashville. 4. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 7. Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. 8. Now withIovance Biotherapeutics, San Carlos, California. 9. Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.
Abstract
Importance: Hematopoietic cell transplantation (HCT) is a potential cure for hematologic cancer but is associated with a risk of relapse and death. Dynamic biomarkers to predict relapse and inform treatment decisions after HCT are a major unmet clinical need. Objective: To identify a quantitative characteristic of leukocyte-endothelial interactions after HCT and test its associations with patient outcomes. Design, Setting, and Participants: In this prospective single-center cohort study from June 2017 to January 2020, patients of any age, sex, race, and ethnicity who had HCT for hematologic cancer were referred by health care professionals as either suspected of having symptoms or not having symptoms of acute graft-vs-host disease between 25 and 161 days after HCT. Patients underwent noninvasive skin videomicroscopy. Videos of dermal microvascular flow were recorded with a reflectance confocal microscope. Two blinded observers (J.R.P. and Z.Z.) counted leukocytes adherent to and rolling along the vessel wall per hour (A&R). Of 57 enrolled patients, 1 relapsed before imaging and was excluded, resulting in 56 patients included in analyses. Main Outcomes and Measures: Relapse of cancer, relapse-free survival, and overall survival. Results: Among the 56 patients (median age, 59 years; 38 [68%] male) who underwent imaging a median of 40 days after HCT, 21 had high A&R and 35 had low A&R. After correcting for the revised Disease Risk Index, patients with high A&R had higher rates of relapse (hazard ratio [HR], 4.24; 95% CI, 1.32-13.58; P = .02), reduced relapse-free survival (HR, 3.29; 95% CI, 1.26-8.55; P = .02), and reduced overall survival (HR, 3.06, 95% CI, 1.02-9.19; P = .05). These associations were preserved after correcting for possible confounders, steroid treatment, and acute graft-vs-host disease status. In the prognostic adequacy calculation by using Cox models, the new imaging biomarker (A&R) accounted for 82% to 95% of the prognostic information to predict each outcome. By contrast, the best existing clinical predictor routinely available, the revised Disease Risk Index, accounted for 10% to 28% of the prognostic information in the same model. Conclusions and Relevance: In this cohort study, leukocyte-endothelial interactions, visualized directly in skin after HCT, were associated with the patient outcomes of relapse, relapse-free survival, and overall survival. Assessing this dynamic marker could help patients at high risk for relapse who may benefit from interventions, such as early withdrawal of immunosuppression.
Importance: Hematopoietic cell transplantation (HCT) is a potential cure for hematologic cancer but is associated with a risk of relapse and death. Dynamic biomarkers to predict relapse and inform treatment decisions after HCT are a major unmet clinical need. Objective: To identify a quantitative characteristic of leukocyte-endothelial interactions after HCT and test its associations with patient outcomes. Design, Setting, and Participants: In this prospective single-center cohort study from June 2017 to January 2020, patients of any age, sex, race, and ethnicity who had HCT for hematologic cancer were referred by health care professionals as either suspected of having symptoms or not having symptoms of acute graft-vs-host disease between 25 and 161 days after HCT. Patients underwent noninvasive skin videomicroscopy. Videos of dermal microvascular flow were recorded with a reflectance confocal microscope. Two blinded observers (J.R.P. and Z.Z.) counted leukocytes adherent to and rolling along the vessel wall per hour (A&R). Of 57 enrolled patients, 1 relapsed before imaging and was excluded, resulting in 56 patients included in analyses. Main Outcomes and Measures: Relapse of cancer, relapse-free survival, and overall survival. Results: Among the 56 patients (median age, 59 years; 38 [68%] male) who underwent imaging a median of 40 days after HCT, 21 had high A&R and 35 had low A&R. After correcting for the revised Disease Risk Index, patients with high A&R had higher rates of relapse (hazard ratio [HR], 4.24; 95% CI, 1.32-13.58; P = .02), reduced relapse-free survival (HR, 3.29; 95% CI, 1.26-8.55; P = .02), and reduced overall survival (HR, 3.06, 95% CI, 1.02-9.19; P = .05). These associations were preserved after correcting for possible confounders, steroid treatment, and acute graft-vs-host disease status. In the prognostic adequacy calculation by using Cox models, the new imaging biomarker (A&R) accounted for 82% to 95% of the prognostic information to predict each outcome. By contrast, the best existing clinical predictor routinely available, the revised Disease Risk Index, accounted for 10% to 28% of the prognostic information in the same model. Conclusions and Relevance: In this cohort study, leukocyte-endothelial interactions, visualized directly in skin after HCT, were associated with the patient outcomes of relapse, relapse-free survival, and overall survival. Assessing this dynamic marker could help patients at high risk for relapse who may benefit from interventions, such as early withdrawal of immunosuppression.
Authors: I Saknite; M Gill; C Alessi-Fox; M Byrne; M Jagasia; S Gonzalez; M Ardigo; E R Tkaczyk Journal: Br J Dermatol Date: 2019-07-15 Impact factor: 9.302
Authors: Nelli Bejanyan; Claudio G Brunstein; Qing Cao; Aleksandr Lazaryan; Celalettin Ustun; Erica D Warlick; Mukta Arora; John E Wagner; Daniel J Weisdorf Journal: Blood Adv Date: 2019-02-12
Authors: Zijun Zhao; James Randall Patrinely; Inga Saknite; Michael Byrne; Eric R Tkaczyk Journal: Microcirculation Date: 2021-09-17 Impact factor: 2.628
Authors: R M Califf; H R Phillips; M C Hindman; D B Mark; K L Lee; V S Behar; R A Johnson; D B Pryor; R A Rosati; G S Wagner Journal: J Am Coll Cardiol Date: 1985-05 Impact factor: 24.094
Authors: Mukta Arora; Corey S Cutler; Madan H Jagasia; Joseph Pidala; Xiaoyu Chai; Paul J Martin; Mary E D Flowers; Yoshihiro Inamoto; George L Chen; William A Wood; Nandita Khera; Jeanne Palmer; Hien Duong; Sally Arai; Sebastian Mayer; Iskra Pusic; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2015-11-02 Impact factor: 5.742
Authors: Anita D'Souza; Caitrin Fretham; Stephanie J Lee; Mukta Arora; Janet Brunner; Saurabh Chhabra; Steven Devine; Mary Eapen; Mehdi Hamadani; Parameswaran Hari; Marcelo C Pasquini; Waleska Perez; Rachel A Phelan; Marcie L Riches; J Douglas Rizzo; Wael Saber; Bronwen E Shaw; Stephen R Spellman; Patricia Steinert; Daniel J Weisdorf; Mary M Horowitz Journal: Biol Blood Marrow Transplant Date: 2020-05-11 Impact factor: 5.609
Authors: Katarzyna Kotfis; Irene van Diem-Zaal; Shawniqua Williams Roberson; Mark van den Boogaard; Yahya Shehabi; E Wesley Ely; Marek Sietnicki Journal: Crit Care Date: 2022-07-05 Impact factor: 19.334